Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:76

Article

Colantonio, Lisandro D.¹  Hubbard, Demetria¹  Monda, Keri L.²  Mues, Katherine E.²  Huang, Lei¹  Dai, Yuling¹  Jackson, Elizabeth A.³  Brown, Todd M.³  Rosenson, Robert S.⁴  Woodward, Mark^5,6,7  Muntner, Paul¹  Farkouh, Michael E.^8,9 

[1] Univ Alabama Birmingham, Dept Epidemiol, 1720 2nd Ave South,RPHB 527C, Birmingham, AL 35294 USA

[2] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA

[3] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA

[4] Icahn Sch Med Mt Sinai, Mt Sinai Heart, New York, NY 10029 USA

[5] Univ Oxford, George Inst Global Hlth, Oxford, England

[6] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia

[7] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA

[8] Univ Toronto, Peter Munk Cardiac Ctr, Toronto, ON, Canada

[9] Heart & Stroke Richard Lewar Ctr Excellence, Toronto, ON, Canada

关键词: atherosclerosis;    cardiovascular disease;    cardiovascular events;    comorbidities;    hydroxymethylglutaryl-CoA reductase inhibitors;    secondary prevention;   

DOI  :  10.1016/j.jacc.2020.05.048

来源: Elsevier

【 摘 要 】

BACKGROUND Peripheral artery disease (PAD) is associated with increased risk for atherosclerotic cardiovascular disease (ASCVD) events. OBJECTIVES The goal of this study was to compare the risk for ASCVD events and the use of statins among patients with PAD versus those with coronary heart disease (CHD) or cerebrovascular disease. METHODS The authors conducted a retrospective cohort study of adults age >= 19 years with commercial or Medicare health insurance who had a history of PAD, CHD, or cerebrovascular disease on December 31, 2014. Patients were followed for ASCVD events comprising CHD, cerebrovascular disease, and PAD events until December 31, 2017. RESULTS Among 943,232 patients included in the analysis, the age-standardized ASCVD event rate per 1,000 personyears for those with a history of 1, 2, and 3 conditions including PAD, CHD, and cerebrovascular disease was 40.8 (95% confidence interval [CI]: 40.3 to 41.3), 68.9 (95% CI: 67.9 to 70.0), and 119.5 (95% CI: 117.0 to 122.0), respectively. The ASCVD event rate among patients with PAD only, CHD only, and cerebrovascular disease only was 34.7 (95% CI: 33.2 to 36.2), 42.2 (95% CI: 41.5 to 42.8), and 38.9 (95% CI: 37.6 to 40.1), respectively. Among patients with PAD and CHD, with PAD and cerebrovascular disease, and with CHD and cerebrovascular disease, the ASCVD event rate was 72.8 (95% CI: 71.0 to 74.7), 63.9 (95% CI: 60.6 to 67.4), and 67.9 (95% CI: 66.4 to 69.3), respectively. Statin use was lower in patients with PAD only (33.9%) versus those with cerebrovascular disease only (43.0%) or CHD only (51.7%). CONCLUSIONS Despite having high risk for ASCVD events, patients with PAD were less likely to be taking a statin versus those with CHD or cerebrovascular disease. ASCVD risk-reduction interventions including statin therapy in patients with PAD are warranted. (c) 2020 by the American College of Cardiology Foundation.

【 授权许可】

Free